Targacept (TRGT) 3.90 $TRGT
Targacept Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 6:35AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today reported its financial results for the first quarter ended March 31, 2014.
Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles
M2 - Fri May 02, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6rgwz8/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Smoking Cessation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Johnson & Johnson - Aradigm Corporation - GlaxoSmithKline plc - Pfizer Inc. - Arena Pharmaceuticals, Inc. - Targacept, Inc. - Invion Limited - Marinus Pharmaceuticals, Inc. - Royalty Pharma - Selecta Biosciences, Inc. - Embera NeuroTherapeutics, Inc. - NAL Pharmaceuticals Ltd. - BIOPROJET SCR - Astraea Therapeutics, LLC - Adial Pharmaceuticals, LLC - Istituto Italiano di Tecnologia Drug Profiles - GSK-598809 - lorcaserin hydrochloride - nadolol - ganaxolone - cycloserine - BP-1.4979 - meclizine hydrochloride - zonisamide - ARD-1600 - (oxazepam metyrapone) - ondansetron - SEL-068 - PF-05402536 - PF-06413367 - cycloserine - Small Molecule for Smoking Cessation - nicotine - NIC7-DT - CC-4 - Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Small Molecule for Smoking Cessation - Alpha 4 Beta 2 Neuronal Nicotinic Receptor Agonists for Smoking Cessation - Small Molecules to Inhibit FAAH for CNS Disorders - Nicotine Vaccine - NAL-2762 For more information visit http://www.researchandmarkets.com/research/6r..._cessation
Targacept Announces Participation in Upcoming Conferences
Business Wire - Thu May 01, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the following conferences:
Targacept to Report First Quarter 2014 Financial Results on May 7, 2014
Business Wire - Wed Apr 30, 7:55AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it will report financial results for the first quarter of 2014 on the morning of Wednesday, May 7, 2014, before the U.S. financial markets open.
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia
Targacept to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference at the Westin New York Grand Central Hotel in New York City on Wednesday, April 9, 2014 at 1:40 p.m. Eastern Time.
Targacept to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, Massachusetts on Wednesday, March 5, 2014 at 8:00 a.m. Eastern Time.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Targacept Reports Fourth Quarter and 2013 Financial Results
Business Wire - Thu Feb 13, 6:30AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today reported its financial results for the fourth quarter and year ended December 31, 2013.
First American Financial Reports Results for the Fourth Quarter and Full Year of 2013
Business Wire - Thu Feb 13, 6:00AM CST
First American Financial Corporation (NYSE: FAF), a leading global provider of title insurance, settlement services and risk solutions for real estate transactions, today announced financial results for the fourth quarter and year ended Dec. 31, 2013.
10-K: MICROSTRATEGY INC
Edgar Online - Wed Feb 12, 3:52PM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Silverpop Launches 2014 Digital Marketing Roadshow Aimed at Helping Marketers Navigate the Customer-Driven World
PR Newswire - Wed Feb 12, 8:20AM CST
Silverpop(TM), a leading provider of digital marketing software that enables personalized customer experiences, today announces the 2014 launch of Digital Marketing University. The series is a global, multi-city educational roadshow aimed at helping marketers of all types thrive in today's ever changing, customer-driven landscape. Silverpop thought leaders and experts from several Silverpop technology and consulting partners will lead discussions to guide marketers along their pursuit to provide customers with a unified, multichannel experience.
Hot Stock: Targacept, Shares Gain 5.5% (TRGT)
Comtex SmarTrend(R) - Mon Feb 10, 11:42AM CST
Targacept (NASDAQ:TRGT) is one of today's best performing low-priced stocks, up 5.5% to $4.96 on 1.1x average daily volume. Targacept has traded 312,000 shares thus far today, vs. average volume of 294,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's -0.1%) and outperformed the S&P 500 (5.5% to the S&P's -0.1%) during today's trading.
Targacept Completes Recruitment in Phase 2b Overactive Bladder Trial of TC-5214
Business Wire - Mon Feb 10, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB). The company expects to report top-line results from the study in mid-2014. TC-5214 acts potently on alpha3beta4 and other neuronal nicotinic receptors (NNRs) located in or around the bladder that are believed to play a key role in bladder contraction and signaling of the urge to urinate.
5 Stocks Poised for Breakouts
at The Street - Fri Feb 07, 1:52PM CST
These stocks are ready to break out and trade higher from current levels.
Targacept to Report Fourth Quarter and 2013 Financial Results on February 13, 2014
Business Wire - Thu Feb 06, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced it will report financial results for the fourth quarter and year ended December 31, 2013 on Thursday, February 13, 2014, before the U.S. financial markets open.
Targacept to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 16th Annual BIO CEO & Investor Conference at The Waldorf Astoria New York in New York City on Tuesday, February 11, 2014 at 2:30 p.m. Eastern Time.
Diabetic Gastroparesis Global Clinical Trials Review, H2 2013 Report Available Now
M2 - Mon Jan 13, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/kd5vzq/diabetic) has announced the addition of the "Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Gastroparesis. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Axcan Pharma, Inc. - Duke University - Evoke Pharma, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Goteborg University - Malmo University Hospital - Novartis AG - Osaka City University - Questcor Pharmaceuticals, Inc. - Rabin Medical Center - Rhythm Pharmaceuticals - Shaare Zedek Medical Center - Targacept, Inc. - Theravance, Inc. - Tranzyme Pharma, Inc. - Vienna General Hospital - Yokohama City University For more information visit http://www.researchandmarkets.com/research/kd5vzq/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Targacept appoints new chairman of the board
AP - Wed Jan 08, 12:15PM CST
WINSTON-SALEM, N.C. (AP) — Targacept Inc. said Wednesday that it has named John Richard as the new chairman of the drugmaker's board of directors.
Targacept Appoints John P. Richard as Chairman of the Board of Directors
Business Wire - Wed Jan 08, 7:54AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that John P. Richard, a Targacept non-executive director since November 2002, has been appointed as the Company's Chairman of the Board effective January 1, 2014. Mr. Richard will continue to serve on the Company's audit and compensation committees.
Targacept Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 6:35AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today reported its financial results for the first quarter ended March 31, 2014.
Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles
M2 - Fri May 02, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6rgwz8/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Smoking Cessation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Johnson & Johnson - Aradigm Corporation - GlaxoSmithKline plc - Pfizer Inc. - Arena Pharmaceuticals, Inc. - Targacept, Inc. - Invion Limited - Marinus Pharmaceuticals, Inc. - Royalty Pharma - Selecta Biosciences, Inc. - Embera NeuroTherapeutics, Inc. - NAL Pharmaceuticals Ltd. - BIOPROJET SCR - Astraea Therapeutics, LLC - Adial Pharmaceuticals, LLC - Istituto Italiano di Tecnologia Drug Profiles - GSK-598809 - lorcaserin hydrochloride - nadolol - ganaxolone - cycloserine - BP-1.4979 - meclizine hydrochloride - zonisamide - ARD-1600 - (oxazepam metyrapone) - ondansetron - SEL-068 - PF-05402536 - PF-06413367 - cycloserine - Small Molecule for Smoking Cessation - nicotine - NIC7-DT - CC-4 - Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Small Molecule for Smoking Cessation - Alpha 4 Beta 2 Neuronal Nicotinic Receptor Agonists for Smoking Cessation - Small Molecules to Inhibit FAAH for CNS Disorders - Nicotine Vaccine - NAL-2762 For more information visit http://www.researchandmarkets.com/research/6r..._cessation
Targacept Announces Participation in Upcoming Conferences
Business Wire - Thu May 01, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the following conferences:
Targacept to Report First Quarter 2014 Financial Results on May 7, 2014
Business Wire - Wed Apr 30, 7:55AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it will report financial results for the first quarter of 2014 on the morning of Wednesday, May 7, 2014, before the U.S. financial markets open.
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia
Targacept to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference at the Westin New York Grand Central Hotel in New York City on Wednesday, April 9, 2014 at 1:40 p.m. Eastern Time.
Targacept to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, Massachusetts on Wednesday, March 5, 2014 at 8:00 a.m. Eastern Time.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Targacept Reports Fourth Quarter and 2013 Financial Results
Business Wire - Thu Feb 13, 6:30AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today reported its financial results for the fourth quarter and year ended December 31, 2013.
First American Financial Reports Results for the Fourth Quarter and Full Year of 2013
Business Wire - Thu Feb 13, 6:00AM CST
First American Financial Corporation (NYSE: FAF), a leading global provider of title insurance, settlement services and risk solutions for real estate transactions, today announced financial results for the fourth quarter and year ended Dec. 31, 2013.
10-K: MICROSTRATEGY INC
Edgar Online - Wed Feb 12, 3:52PM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Silverpop Launches 2014 Digital Marketing Roadshow Aimed at Helping Marketers Navigate the Customer-Driven World
PR Newswire - Wed Feb 12, 8:20AM CST
Silverpop(TM), a leading provider of digital marketing software that enables personalized customer experiences, today announces the 2014 launch of Digital Marketing University. The series is a global, multi-city educational roadshow aimed at helping marketers of all types thrive in today's ever changing, customer-driven landscape. Silverpop thought leaders and experts from several Silverpop technology and consulting partners will lead discussions to guide marketers along their pursuit to provide customers with a unified, multichannel experience.
Hot Stock: Targacept, Shares Gain 5.5% (TRGT)
Comtex SmarTrend(R) - Mon Feb 10, 11:42AM CST
Targacept (NASDAQ:TRGT) is one of today's best performing low-priced stocks, up 5.5% to $4.96 on 1.1x average daily volume. Targacept has traded 312,000 shares thus far today, vs. average volume of 294,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's -0.1%) and outperformed the S&P 500 (5.5% to the S&P's -0.1%) during today's trading.
Targacept Completes Recruitment in Phase 2b Overactive Bladder Trial of TC-5214
Business Wire - Mon Feb 10, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB). The company expects to report top-line results from the study in mid-2014. TC-5214 acts potently on alpha3beta4 and other neuronal nicotinic receptors (NNRs) located in or around the bladder that are believed to play a key role in bladder contraction and signaling of the urge to urinate.
5 Stocks Poised for Breakouts
at The Street - Fri Feb 07, 1:52PM CST
These stocks are ready to break out and trade higher from current levels.
Targacept to Report Fourth Quarter and 2013 Financial Results on February 13, 2014
Business Wire - Thu Feb 06, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced it will report financial results for the fourth quarter and year ended December 31, 2013 on Thursday, February 13, 2014, before the U.S. financial markets open.
Targacept to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 16th Annual BIO CEO & Investor Conference at The Waldorf Astoria New York in New York City on Tuesday, February 11, 2014 at 2:30 p.m. Eastern Time.
Diabetic Gastroparesis Global Clinical Trials Review, H2 2013 Report Available Now
M2 - Mon Jan 13, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/kd5vzq/diabetic) has announced the addition of the "Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Gastroparesis. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Axcan Pharma, Inc. - Duke University - Evoke Pharma, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Goteborg University - Malmo University Hospital - Novartis AG - Osaka City University - Questcor Pharmaceuticals, Inc. - Rabin Medical Center - Rhythm Pharmaceuticals - Shaare Zedek Medical Center - Targacept, Inc. - Theravance, Inc. - Tranzyme Pharma, Inc. - Vienna General Hospital - Yokohama City University For more information visit http://www.researchandmarkets.com/research/kd5vzq/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Targacept appoints new chairman of the board
AP - Wed Jan 08, 12:15PM CST
WINSTON-SALEM, N.C. (AP) — Targacept Inc. said Wednesday that it has named John Richard as the new chairman of the drugmaker's board of directors.
Targacept Appoints John P. Richard as Chairman of the Board of Directors
Business Wire - Wed Jan 08, 7:54AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that John P. Richard, a Targacept non-executive director since November 2002, has been appointed as the Company's Chairman of the Board effective January 1, 2014. Mr. Richard will continue to serve on the Company's audit and compensation committees.
